Afficher la couverture 'Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial | Culine, Stéphane' en grand format
/5

0 avis

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Archive ouverte

Culine, Stéphane | Harter, Valentin | Gravis, Gwenaelle | Fléchon, Aude | Chevreau, Christine | Mahammedi, Hakim | Laguerre, Brigitte | Guillot, Aline | Joly, Florence | Abadie-Lacourtoisie, Sophie | Geoffrois, Lionnel | Di Fiore, Frederic | Roubaud, Guilhem | Barthélémy, Philippe | Voog, Eric | Emambux, Sheik | Serrate, Camille | Saldana, Carolina | Hon, Thierry Nguyen Tan | Loriot, Yohann | Eymard, Jean-Christophe | Huillard, Olivier | Rolland, Frédéric | Houédé, Nadine | Spano, Jean-Philippe | Demery, Mounira El | Vieillot, Sabine | L'Haridon, Tifenn | Hilgers, Werner | Allory, Yves | Pfister, Christian

Edité par CCSD ; Elsevier -

International audience. Background: Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date.Patients and methods: In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance (CrCl) was calculated before each cycle according to the Cockroft and Gault formula. Definition criteria for local control after neoadjuvant chemotherapy included pathological complete response (ypT0N0), pathological downstaging (

Suggestions

Du même auteur

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Archive ouverte | Pfister, Christian | CCSD

International audience. Background: The optimal perioperative chemotherapy for patients with muscle-invasive bladder cancer is not defined. The VESPER (French Genito-Urinary Tumor Group and French Association of Uro...

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study

Archive ouverte | Culine, Stéphane | CCSD

International audience. This study looked at whether epidermal growth factor receptor inhibition by the monoclonal antibody panitumumab could increase the efficacy of standard chemotherapy in advanced urothelial can...

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Archive ouverte | Culine, Stéphane | CCSD

International audience. Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy and pelvic lymph node dissection is the optimal treatment for patients with muscle-invasive bladder cancer. In re...

Chargement des enrichissements...